BIIB Share Price

Open 311.30 Change Price %
High 319.34 1 Day 3.43 1.09
Low 311.30 1 Week -2.80 -0.87
Close 318.46 1 Month 35.82 12.67
Volume 972554 1 Year 5.88 1.88
52 Week High 330.00
52 Week Low 244.28
BIIB Important Levels
Resistance 2 325.91
Resistance 1 322.84
Pivot 316.37
Support 1 314.08
Support 2 311.01
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
ASTI 0.00 0.00%
More..
NASDAQ USA Top Gainers Stocks
RITT 0.02 100.00%
LOCM 0.09 50.00%
NETE 0.72 44.00%
SCHS 0.04 33.33%
MRGE 0.55 30.95%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PGRX 0.05 25.00%
ESMC 0.12 20.00%
More..
NASDAQ USA Top Losers Stocks
DEER 0.00 -100.00%
CAFI 0.00 -100.00%
ORIG 24.00 -96.52%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CPWR 1.00 -60.00%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
More..

Biogen Idec Inc. (NASDAQ: BIIB)

BIIB Technical Analysis 5
As on 22nd Sep 2017 BIIB Share Price closed @ 318.46 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 283.44 & Strong Buy for SHORT-TERM with Stoploss of 295.68 we also expect STOCK to react on Following IMPORTANT LEVELS.
BIIB Target for September
1st Target up-side 336.32
2nd Target up-side 350.16
3rd Target up-side 364.01
1st Target down-side 296.8
2nd Target down-side 282.96
3rd Target down-side 269.11
BIIB Other Details
Segment EQ
Market Capital 33194547200.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.biogenidec.com
BIIB Address
BIIB
225 Binney Street
Cambridge, MA 02142
United States
Phone: 781-464-2000
BIIB Latest News
Interactive Technical Analysis Chart Biogen Idec Inc. ( BIIB NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Biogen Idec Inc.
BIIB Business Profile
Biogen Idec Inc. (Biogen Idec) is a global biotechnology company. The Company discovers, develops, manufactures and markets therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. The Company’s products include AVONEX, TYSABRI, FAMPYRA, FUMADERM and RITUXAN. In September 2011, the Company acquired from the Dompe Group the noncontrolling interests in its joint venture sales affiliates in Italy and Switzerland. In April 2013, Elan Corporation, plc closed the TYSABRI (natalizumab) Collaboration Transaction with Biogen Idec.